• PN: A111419T

COMPONENTS

45x Ab-conjugated beads (S5P7 - human IL-33 Ab-bead). PN: A111419TA. One vial containing 35 µL of anti-human IL-33 conjugated to AimPlex Bead S5P7.

25x Biotin-detection Ab (human IL-33 Biotin-dAb). PN: A111419TB. One vial containing 35 µL of biotinylated anti-human IL-33.

Lyophilized Standard Mix-Human Group 2 Panel B, 10-Plex. PN: HG20010. One vial containing lyophilized recombinant human IL-17F, IL-20, IL-21, IL-28A, IL-29, IL-33, M-CSF, MPO, TSLP, and VEGF-A. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human IL-33.  Can be multiplexed with other analytes in Human Group 2.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 2: Negligible

Sample volume: 15 µL/test

Description:

Interleukin 33 (IL-33) is a cytokine belonging to the IL-1 superfamily.  IL-33 induces helper T cells, mast cells, eosinophils and basophils to produce type 2 cytokines. This cytokine was previously named NF-HEV 'nuclear factor (NF) in high endothelial venules' (HEVs) since it was originally identified in these specialized cells. IL-33 is expressed on a wide variety of cell types, including fibroblasts, mast cells, dendritic cells, macrophages, osteoblasts, endothelial cells, and epithelial cells. IL-33 mediates its biological effects by interacting with the receptors ST2 (also known as IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. The induction of type 2 cytokines by IL-33 in vivo is believed to induce the severe pathological changes observed in mucosal organs following administration of IL-33.

References:

1.      PDB: 2KLL; Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, Bazan JF, Fairbrother WJ (October 2009). "Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes". Structure 17 (10): 1398–410. doi:10.1016/j.str.2009.08.009. PMC 2766095. PMID 19836339.

2.      Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K, Saito H, Matsuda A (November 2010). "IL-33 mediates inflammatory responses in human lung tissue cells". J. Immunol. 185 (10): 5743–50. doi:10.4049/jimmunol.0903818. PMID 20926795.

3.      Mirchandani, A; Salmond, R; Liew, F (2012). "Interleukin-33 and the function of innate lymphoid cells". Trends in Immunology 33 (8): 389–396. doi:10.1016/j.it.2012.04.005.

4.      Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M, Haraldsen G, Girard JP (July 2003). "Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules". Am. J. Pathol. 163 (1): 69–79. doi:10.1016/S0002-9440(10)63631-0. PMC 1868188. PMID 12819012.